Heat Biologics develops off-the-shelf immunotherapy products that reprogram tumor cells to pump out antigens and stimulate an immune response. Its lead program is an experimental lung cancer therapy currently in a phase 2 clinical trial. The company also plans phase 1 trials for bladder and ovarian cancer indications. Heat positions its treatments as non‑patient‑specific, which the company says reduces cost versus personalized cell therapies. CEO Jeff Wolf noted the company was founded in 2008 and framed its work in the context of broader advances in immunotherapy. Heat announced a $10 million Series B to finance clinical development across its three programs.

Total raised

$10M

Funding rounds

1

Latest round

Series B

Latest activity

Feb 2012